GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Braftovi® | LGX-818 | LGX818
                                 
                                                         
                            
                            
                            
                                 
                                
                                encorafenib is an approved drug (FDA and EMA (2018)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Encorafenib (LGX-818) is an orally available BRAF kinase inhibitor with antineoplastic activity.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R et al.. (2018)
                                         Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 19 (5): 603-615. [PMID:29573941]  | 
                                                                
| 
                                                                         2. Stuart DD, Li N, Poon DJ, Aardalen K, Kaufman S, Merritt H, Salangsang F, Lorenzana E, Li A, Ghoddusi M et al.. (2012)
                                         Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor [Abstract]. Proceedings: AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL. Cancer Research, 72 (8 (Supplement 1)): Abstract 3790.  |